1.56 USD
+0.02 (+1.3%)
1.56 USD
0 (0%)
SKIN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 36 industry peers in the Personal Care Products industry. SKIN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SKIN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year SKIN has reported negative net income.
- SKIN had a positive operating cash flow in the past year.
- SKIN had negative earnings in 4 of the past 5 years.
- In multiple years SKIN reported negative operating cash flow during the last 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -2.33%, SKIN is in line with its industry, outperforming 41.67% of the companies in the same industry.
- SKIN has a worse Return On Equity (-17.89%) than 61.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.33% | ||
| ROE | -17.89% | ||
| ROIC | N/A |
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SKIN's Gross Margin of 66.57% is in line compared to the rest of the industry. SKIN outperforms 50.00% of its industry peers.
- In the last couple of years the Gross Margin of SKIN has declined.
- SKIN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SKIN has more shares outstanding
- SKIN has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -0.11, we must say that SKIN is in the distress zone and has some risk of bankruptcy.
- SKIN's Altman-Z score of -0.11 is on the low side compared to the rest of the industry. SKIN is outperformed by 77.78% of its industry peers.
- SKIN has a debt to FCF ratio of 10.65. This is a negative value and a sign of low solvency as SKIN would need 10.65 years to pay back of all of its debts.
- SKIN has a Debt to FCF ratio (10.65) which is comparable to the rest of the industry.
- SKIN has a Debt/Equity ratio of 5.53. This is a high value indicating a heavy dependency on external financing.
- SKIN has a worse Debt to Equity ratio (5.53) than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.53 | ||
| Debt/FCF | 10.65 | ||
| Altman-Z | -0.11 |
ROIC/WACCN/A
WACC6.73%
2.3 Liquidity
- A Current Ratio of 4.98 indicates that SKIN has no problem at all paying its short term obligations.
- SKIN's Current ratio of 4.98 is amongst the best of the industry. SKIN outperforms 88.89% of its industry peers.
- SKIN has a Quick Ratio of 4.07. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
- SKIN has a Quick ratio of 4.07. This is amongst the best in the industry. SKIN outperforms 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.98 | ||
| Quick Ratio | 4.07 |
3. Growth
3.1 Past
- SKIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.18%.
- SKIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.15%.
- The Revenue has been growing by 8.72% on average over the past years. This is quite good.
EPS 1Y (TTM)-30.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-13.15%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-10.34%
3.2 Future
- The Earnings Per Share is expected to grow by 33.71% on average over the next years. This is a very strong growth
- SKIN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.40% yearly.
EPS Next Y54.41%
EPS Next 2Y22.72%
EPS Next 3Y-1.31%
EPS Next 5Y33.71%
Revenue Next Year-9.74%
Revenue Next 2Y-2.93%
Revenue Next 3Y-0.97%
Revenue Next 5Y1.4%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SKIN. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of SKIN indicates a rather cheap valuation: SKIN is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.83 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.72%
EPS Next 3Y-1.31%
5. Dividend
5.1 Amount
- No dividends for SKIN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.56
+0.02 (+1.3%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-10 2026-03-10/amc
Inst Owners88.15%
Inst Owner Change-0.04%
Ins Owners11.44%
Ins Owner Change10.21%
Market Cap198.90M
Revenue(TTM)301.92M
Net Income(TTM)-11.74M
Analysts51.43
Price Target1.97 (26.28%)
Short Float %14.97%
Short Ratio17.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)62.73%
Min EPS beat(2)-30.18%
Max EPS beat(2)155.64%
EPS beat(4)3
Avg EPS beat(4)47.59%
Min EPS beat(4)-30.18%
Max EPS beat(4)155.64%
EPS beat(8)7
Avg EPS beat(8)51.89%
EPS beat(12)10
Avg EPS beat(12)48.9%
EPS beat(16)13
Avg EPS beat(16)418.68%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)0.99%
Max Revenue beat(2)2.9%
Revenue beat(4)4
Avg Revenue beat(4)4.15%
Min Revenue beat(4)0.99%
Max Revenue beat(4)6.94%
Revenue beat(8)6
Avg Revenue beat(8)2.34%
Revenue beat(12)7
Avg Revenue beat(12)-0.39%
Revenue beat(16)11
Avg Revenue beat(16)2.61%
PT rev (1m)0%
PT rev (3m)-14.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.33%
EPS NY rev (1m)0%
EPS NY rev (3m)33.33%
Revenue NQ rev (1m)-0.99%
Revenue NQ rev (3m)-0.12%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.66 | ||
| P/FCF | 5.83 | ||
| P/OCF | 5.13 | ||
| P/B | 3.03 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)0.27
FCFY17.15%
OCF(TTM)0.3
OCFY19.49%
SpS2.37
BVpS0.51
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.33% | ||
| ROE | -17.89% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.57% | ||
| FCFM | 11.3% |
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.53 | ||
| Debt/FCF | 10.65 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 20.73% | ||
| Cap/Sales | 1.54% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.98 | ||
| Quick Ratio | 4.07 | ||
| Altman-Z | -0.11 |
F-Score6
WACC6.73%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y54.41%
EPS Next 2Y22.72%
EPS Next 3Y-1.31%
EPS Next 5Y33.71%
Revenue 1Y (TTM)-13.15%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-10.34%
Revenue Next Year-9.74%
Revenue Next 2Y-2.93%
Revenue Next 3Y-0.97%
Revenue Next 5Y1.4%
EBIT growth 1Y16.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.5%
EBIT Next 3Y34.45%
EBIT Next 5Y34.66%
FCF growth 1Y335.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.03%
OCF growth 3YN/A
OCF growth 5YN/A
BEAUTY HEALTH CO/THE / SKIN FAQ
Can you provide the ChartMill fundamental rating for BEAUTY HEALTH CO/THE?
ChartMill assigns a fundamental rating of 2 / 10 to SKIN.
What is the valuation status of BEAUTY HEALTH CO/THE (SKIN) stock?
ChartMill assigns a valuation rating of 2 / 10 to BEAUTY HEALTH CO/THE (SKIN). This can be considered as Overvalued.
Can you provide the profitability details for BEAUTY HEALTH CO/THE?
BEAUTY HEALTH CO/THE (SKIN) has a profitability rating of 1 / 10.
Can you provide the financial health for SKIN stock?
The financial health rating of BEAUTY HEALTH CO/THE (SKIN) is 4 / 10.
What is the earnings growth outlook for BEAUTY HEALTH CO/THE?
The Earnings per Share (EPS) of BEAUTY HEALTH CO/THE (SKIN) is expected to grow by 54.41% in the next year.